Active Ingredient(s): Entrectinib
FDA Approved: * August 15, 2019
Pharm Company: * GENENTECH INC
Category: Cancer

Entrectinib, sold under the brand name Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors.[3] It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK).[3] The most common side effects include tiredness, constipation, dysgeusia (taste disturbances), edema (swelling with flui... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Rozlytrek 100 mg Oral Capsule
NDC: 50242-091
Genentech Inc.
Rozlytrek 200 mg Oral Capsule
NDC: 50242-094
Genentech Inc.
Rozlytrek 50 mg/mg Oral Pellet
NDC: 50242-623
Genentech, Inc.